^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Excerpt:
Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas.
DOI:
10.1038/ncomms6694